8-K: Mangoceuticals Sees Series B Preferred Stock Conversions into Common Stock

Mangoceuticals, Inc. reports the conversion of Series B Convertible Preferred Stock into common stock by several holders, impacting the company's equity structure.

Summary

• On March 25 and 26, 2025, holders of Mangoceuticals' Series B Convertible Preferred Stock converted their shares into common stock.
• The conversions occurred at a price of $1.50 per share.
• A total of 830 shares of Series B Convertible Preferred Stock, with an aggregate stated value of $913,000, were converted into 608,668 shares of common stock.
• The company claims an exemption from registration under Section 3(a)(9) of the Securities Act of 1933 for these issuances.

Sentiment

Score: 5

Explanation: The document describes a routine financial transaction (stock conversion). It's neither particularly positive nor negative, hence a neutral score.

Risks

• The conversion of preferred stock into common stock dilutes existing shareholders' ownership.

Industry Context

Conversions of preferred stock to common stock are a common financial maneuver, often reflecting investor confidence or strategic decisions regarding capital structure.

Stakeholder Impact

• Existing shareholders may experience dilution due to the increase in the number of outstanding common shares.

Key Dates

Keywords

Series B Convertible Preferred Stock, Common Stock, Conversion, Equity Securities, Mangoceuticals, MGRX